Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154


The pyrazinamide susceptibility breakpoint above which combination therapy fails.

Gumbo T, Chigutsa E, Pasipanodya J, Visser M, van Helden PD, Sirgel FA, McIlleron H.

J Antimicrob Chemother. 2014 Sep;69(9):2420-5. doi: 10.1093/jac/dku136. Epub 2014 May 12.


Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ.

Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158.


Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.

Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H.

Antimicrob Agents Chemother. 2015 Jan;59(1):38-45. doi: 10.1128/AAC.03931-14. Epub 2014 Oct 13.


Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.

Zheng X, Zheng R, Hu Y, Werngren J, Forsman LD, Mansjö M, Xu B, Hoffner S.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4786-92. doi: 10.1128/AAC.03008-15. Print 2016 Aug.


Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.

Bwire R, Borgdorff MW, Sticht-Groh V, Rieder HL, Kawuma HJ, Bretzel G, Rüsch-Gerdes S.

East Afr Med J. 1999 Jun;76(6):307-13.


Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Werngren J, Sturegård E, Juréen P, Ängeby K, Hoffner S, Schön T.

Antimicrob Agents Chemother. 2012 Mar;56(3):1253-7. doi: 10.1128/AAC.05894-11. Epub 2011 Dec 27.


Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.

Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, Zhang Y.

Antimicrob Agents Chemother. 2012 Nov;56(11):5465-75. doi: 10.1128/AAC.01300-12. Epub 2012 Aug 6.


Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics.

Wilkinson D, Pillay M, Davies GR, Sturm AW.

Trans R Soc Trop Med Hyg. 1996 Nov-Dec;90(6):692-5.


Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.

Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsåker T, Muthivhi T, Weyer K, Fourie PB, Grewal HM.

J Clin Microbiol. 2008 Oct;46(10):3459-64. doi: 10.1128/JCM.00973-08. Epub 2008 Aug 27.


Primary and acquired pyrazinamide resistance in patients with pulmonary tuberculosis treated at a referral hospital in the city of Recife, Brazil.

Ribeiro LB, Magalhães V, Magalhães M.

J Bras Pneumol. 2012 Nov-Dec;38(6):740-7. English, Portuguese.


Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients.

Sheen P, Méndez M, Gilman RH, Peña L, Caviedes L, Zimic MJ, Zhang Y, Moore DA, Evans CA.

J Clin Microbiol. 2009 Sep;47(9):2937-43. doi: 10.1128/JCM.01594-08. Epub 2009 Jun 17.


Treating pyrazinamide mono-resistant pulmonary tuberculosis.

Pérez-Guzmán C, Vargas MH, Pérez-Arellano CP, García-Toledo D.

Int J Tuberc Lung Dis. 2013 Sep;17(9):1244-5. doi: 10.5588/ijtld.13.0166. No abstract available.


Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.

Wang JY, Lee LN, Yu CJ, Chien YJ, Yang PC; Tami Group.

Respirology. 2009 Sep;14(7):1012-9. doi: 10.1111/j.1440-1843.2009.01598.x. Epub 2009 Jul 30.


A quantitative adaptation of the Wayne test for pyrazinamide resistance.

Meinzen C, Proaño A, Gilman RH, Caviedes L, Coronel J, Zimic M, Sheen P.

Tuberculosis (Edinb). 2016 Jul;99:41-6. doi: 10.1016/ Epub 2016 Apr 6.


14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK.

Lancet. 2012 Sep 15;380(9846):986-93. doi: 10.1016/S0140-6736(12)61080-0. Epub 2012 Jul 23.


Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.

Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6766-6773. doi: 10.1128/AAC.00632-16. Print 2016 Nov. Erratum in: Antimicrob Agents Chemother. 2017 Feb 23;61(3):.


Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.

Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1335-43. doi: 10.5588/ijtld.11.0811.


Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis.

Su WJ, Feng JY, Chiu YC, Huang SF, Lee YC.

Eur Respir J. 2011 Feb;37(2):376-83. doi: 10.1183/09031936.00007410. Epub 2010 Jun 1.


Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media.

Schaberg T, Reichert B, Schülin T, Lode H, Mauch H.

Eur Respir J. 1995 Oct;8(10):1688-93.

Supplemental Content

Support Center